Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

dic(5;17)(q11-14;p11-13)

Written2016-12Adriana Zamecnikova, Soad al Bahar
Kuwait Cancer Control Center, Department of Hematology annaadria@yahoo.com

Abstract Complete or partial monosomies of the long arm of chromosome 5 and/or 17p are common findings in myeloid malignancies, particularly in therapy-related myeloid disorders. They usually result from interstitial or terminal deletions and less frequently from unbalanced rearrangements such as dicentric chromosomes. One of the recurring unbalanced translocation in myeloid malignancies is the unbalanced dicentric translocation dic(5;17)(q11-14;p11-13) that results in complete or partial monosomy for the long arm of chromosome 5 and the short arm of chromosome 17.

Keywords dicentric; chromosome 5; chromosome 17; chronic myelogenous leukemia; acute myeloid leukemia; myelodysplastic syndrome; therapy-related leukemmia.

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424
ICD-Morpho 9975/3 Chronic myelogenous leukaemia, BCR-ABL1 positive; Myeloproliferative neoplasm, unclassifiable; Myelodysplastic/myeloproliferative neoplasm, unclassifiable
ICD-Morpho 9989/3 Myelodysplastic syndrome, unclassifiable
ICD-Morpho 9920/3 Therapy-related myeloid neoplasms
ICD-Morpho 9861/3 AML with mutated NPM1; AML with mutated CEBPA; Acute myeloid leukaemia, NOS
Atlas_Id 1164
Note Included are 5q11-14 and 17p11-13 breakpoints (breakpoints described at or near the centromeres), the related unbalanced der(5)t(5;17) and der(17)t(5;17) are not included.
 
  Figure 1 dic(5;17)(q11.2~13;p11.2~13) G- banding: - Courtesy Ronnie Ghuman and Charles D. Bangs.

Clinics and Pathology

Disease Chronic myeloproliferative neoplasms and acute myeloid leukemia (AML)
16 patients had a primary myelodysplastic syndrome (MDS) (Knapp et al., 1985; Herry et al., 2007; Lange et al., 2010) or de novo AML (Huret et al., 1991; Kwong et al., 1994; Arkesteijn et al., 1996; Tosi et al 1996; Wang et al., 1997; Mrozek et al., 2002; Zatkova et al., 2006; Herry et al., 2007; Hangai et al., 2013) and 2 patients had chronic myelogenous leukemia in advanced phase (Hagemeijer et al., 1981; Wang et al., 1997). 23 patients developed therapy-related MDS (Hatzis et al., 1995; Wang et al 1997; Andersen et al., 2005; Andersen et al., Andersen et al., 2008) or AML (Kerim et al., 1991; Heyn et al., 1994; Wang et al., 1997; Nakamori et al., 2003; Andersen et al., 2005; McNerney et al., 2014) after cytotoxic treatment and/or radiotherapy (Table 1).
Table 1. Reported patients with dic(5;17)(q11-14;p11-13).
 Sex/AgeDiagnosisKaryotype
1M/26CML44-45,XY,dic(5;17)(q11;p11),t(9;22),r(18)
blast crisis
2M/57RAEB45,XY,dic(5;17)(q11;p11),-7,+8/46,idem,add(18)(q23),+mar
3M/69AML-M245,XY,r(3),dic(5;17)(q14;p13),del(7)(q11),add(9)(p2?),add(9)(q34),-12,-13,i(21)(q10),+mar/90,idemx2
4M/71AML-M147,XY,+8/44,XY,-5,-17,-18,+mar/44,XY,dic(5;17)(q11;p11),-18/46,XY,dic(5;17),-18,+mar
idiopathic myelofibrosis, chemotherapy
5M/1AML45,XY,hsr(2)(q22),dic(5;17)(q11;p11),der(7)del(7)(q11)hsr(7)(q11),der(12)t(12;19)(p11;q12),-19, +mar
embryonal rhabdomyosarcoma, chemotherapy, radiotherapy
6M/77AML-M147,XY,+14/45,XY,dic(5;17)(q11;p11),dmin/95-96,XXY,-Y,-5,+9,+11,+12,+13,+13, +14,+14,+ 17
7F/59RAEB45,XX,dic(5;17)(q11;p11)
acute promyelocytic leukemia, relapse, chemotherapy
8M/45AML-M146,XY,t(1;15)(p21;q23),t(3;5)(q23;q12),ins(4;12)(q28;p?),dic(5;17)(q11;p11),der(7)t(7;18)(q11;q12)t(14;18)(q12;q23),+8,-14,del(18)(q12q23),add(19)(q23), +21
9F/63AML46,XX,dic(5;17)(q11;p11),-7,der(10)t(10;19)(p11;q11),-19,+2mar
10M/75AML46,XY,-3,dic(5;17)(q11;p11),del(7)(q22q?),+8,+11,-15,+mar
11M/66AML-M643,XY,der(5)t(5;12)(q13;q14),dic(5;17)(q13;p11),-7,dup(9)(q21q12),-12,-15, add(16)(q13),add(17)(p11),-18, +add(21)(p11),+mar/44,idem,+13
12F/64MDS45,XX,-7/45,XX,dic(5;17)(q11;p11)/44,XX,dic(5;17),der(7)t(7;13)(q11;q14), add(13)(q14),-17/44,XX,-3, dic(5;17),der(7)t(3;7)(p14;q32)/44,XX,-3,der(5)t (5;7)(q11;p1?5),dic(5;17),der(7)t(7;16)(p1?5;p13)t(3;7), der(16;17)t(16;17)(p13;p11)ins(16;5)(p13;q11q11),add(21)(q22)
adenocarcinoma, chemotherapy, radiotherapy
13F/50AML45,XX,dic(5;17)(q13;p11),inv(5)(p13q11)/46,idem,+8/44,idem,-11,add(16)(p13),der(19)t(11;19)(q11q25;p13) add(11)(q11)
 multiple myeloma, chemotherapy
14F/64AML45,XX,add(1)(q42),add(4)(q2?5),dic(5;17)(q11;p11),der(6)t(6;12)(q21;q21),-12,+mar/46,idem,+8/46,idem,+11, der(11;11)t(11;11)(p15;q25)ins(11;?)(p15;?)/46,idem,+11,der(11;11),+13,-mar,+mar
adenocarcinoma, chemotherapy
15F/73AML43,XX,dic(3;22)(p21;p11),dic(5;17)(q11;p11),-7,+8,add(12)(p13),add(14)(p11), -16/44,idem,+mar
adenocarcinoma, radiotherapy
16F/48MDS46,XX,t(8;17)(p11;q22) or t(8;17)(p21;q23)/46,XX,del(7)(q22q34)/46,XX,t(2;18)(p21;p11)/ 46,XX,t(2;12)(q11;q21-22),t(11;17)(q13;q25)/45,XX,del(1) (p34p36),dic(5;17)(q13;p11),+8,-18
follicular lymphoma, chemotherapy, radiotherapy
17M/55MDS44,XY,dic(5;17)(q13;p11),dic(19;20)(p13;q11)/45,idem,+mar
Hodgkin disease, chemotherapy
18F/81MDS47,XX,del(3)(p21p24),dic(5;17)(q13;p11),+8,+22/48,idem,+X
adenocarcinoma, radiotherapy
19M/58MDS45,XY,dic(5;17)(q11;p11),r(7)(p2?2q1?1)/45,idem,dic(5;17),i(9)(p10),del(13)(q12q14)/43,XY,dic(5;17),-7, dic(9;18)(q13;p11)/44,XY,dic(5;17),-7/46,XY,del(11)(q14q23)
chronic lymphocytic leukemia, chemotherapy
20M/73AML43,XY,-3,dic(5;17)(q11;p11),-7,+12,t(12;?12)(p13;q13-14),-18,+19,-22/42, idem,-12,del(22)(q11)/43,idem,-12,
21M/57AML-M747,XY,dic(5;17)(q11;p11),-7,-13,add(19)(p13),+4mar
22M/59CML45,XY,dic(5;17)(q11;p11),del(9)(q34) or del(9)(q34q34),t(9;22)(q34;q11)/45,idem,+22/45,XY,t(9;22),der(18) t(17;18)(q11;p11)
23M/25AML44,XY,del(3)(p13),dic(5;17)(q11;p11),-7
Hodgkin disease, chemotherapy, radiotherapy
24M/8AML45,XY,dic(5;17)(q11;p11),del(7)(q22q35)/46,idem,+21/44,idem,der(11;21)t(11;21)(p15;p13) ins(11;?)(p15;?) add(11)(q22)
rhabdomyosarcoma, chemotherapy, radiotherapy
25M/48AML-M245-46,XY,der(5)t(5;17)(q11;q11),r(11;11)(p15q25;q?),-17,+mar/47,idem,+der(5)t(5;17)(q11;q11)/44,XY,der(4) t(4;11)(q3?5;q13)ins(4;11)(q3?5;?)t(11;11)(q25;?),der(5)t(5;17),-11,-17/42,XY,dic(5;17)(q11;p11-12),-7,der(11)del(11)(q13q23)dup(11)(q24q22)t(11;12)(q2?2;q22),-12,der(16)del(16)(q22q24)?dup(16)(q24q24)t(7;16(q11;q24),-18 ?
26M/54AML-M644,XY,dic(5;17)(q13;p11),-7,add(15)(q24)/44,idem,-dic(5;17),+mar
43,XY,dic(5;17),-7,add(12)(p11),add(15)(q24),-16
56,XY,+Y,+1,+2,add(3)(p13),add(4)(p11),+6,+14,+15,add(15)x2,add(19)(p13), +20,+4mar/113-116,idemx2,+8,+8,+5mar
adenocarcinoma, chemotherapy
27M/62AML-M143-47,X,-Y,dic(5;17)(q11;p11),der(5;17)t(5;17)t(13;17)(q?14;q?),-7,der(9)t(9;12)(q34;q?13),+der(10)del(10)(p?)del(10)(q?),-12,der(13;21)(q10;q10),i(13)(q10), der(18)t(14;18)(q?;p?)t(14;21)(q?24;q?11),der(18)t(9;18)(?;p11)t(9;14)t(9;21)
Wegeners granulomatosis, chemotherapy
28M/69MDS46,X,t(Y;16)(q12;q?),del(3)(p24p?),del(5)(q31q31),dic(5;17)(q11;p11),dup(19)(q?),+del(21)(q21)/48,idem,+18, +19,-dup(19),+22
Hodgkin disease, chemotherapy, radiotherapy
29F/53MDS43,XX,dic(5;17)(q11;p11),dic(6;19)(p2?4;?),-21/43,XX,dic(5;17),-7,ider(21)(q10)del(21)(q22),-22,der(22)t(9;22)(q?;p11)
adenocarcinoma, chemotherapy
30F/86AML44,XX,dic(5;17)(q11;p11),-7,der(10)t(10;11)(q25;q22)/43,idem,del(3)(p21),dic(4;7)(q11;q11),+7,der(8)t(4;8) (q21;p21),-12,der(12)t(12;21)(p13;q22),der(21)t(12;21)(q?;q21)/43,idem,del(3),dic(4;7),+7,der(8)t(4;8),dup(11)(q23q23),-12,der(12)t(12;21),der(21)t(12;21)
adenocarcinoma, chemotherapy
31M/73AML44,XY,dic(5;17)(q11;p11),der(6)del(6)(p?)del(6)(q?),dup(6)(q?),-7,dup(8)(p?),ins(9;5)(q34;q31q31)
Hodgkin disease, chemotherapy, radiotherapy
32M/39AML-M145,XY,dic(5;17)(q11;p11),+11,-19,der(20)t(19;20)t(19;20)/43,idem,-11,-16/43-46,idem,dic(3;15)(p11;p11),-4, der(19)t(4;19)(?;q?),der(20)t(19;20)t(4;19)
Hodgkin disease, chemotherapy, radiotherapy
33M/76MDS45,XY,dic(5;17)(q11;p11),+6,der(6)t(6;11)(p23;q14-21)x2,del(7)(q22),dic(15;16)(p11;q11)/45,idem,+del(7)(q31),-del(7)(q22),+dup(7)(q31q31)/45,idem, +15,-dic(15;16),+del(16)(q12),-18
Hodgkin disease, chemotherapy
34M/72AML-M147-49,XY,der(2;7)dic(2;7)(p23;q11)t(2;12)(q33;q11),dic(5;17)(q11;p12),+8,+r(11)x3,der(12)t(2;12)(p23;q11),+13
35F/32MDS45,XX,dic(5;17)(q11;p11),-7,+r/45,idem,add(14)(p11)
36F/79MDS46,XX,dic(5;7)(q11;p11),idic(5)(q11),r(5),?dic(7;8)(q31;p22),?dic(12;17)(p12;q22)
37M/69AML-M246,XY,dic(5;17)(q11;p11),-7,+add(11)(q25),+13,del(13)(q31)x2,-16,-17,-18, +3mar
38M/69MDS46,X,t(Y;16)(q12;q?),del(3)(p24p?),del(5)(q13q31),dic(5;17)(q11;p11),dup(19)(q?),+del(21)(q21)/48,idem,+18,+19,-dup(19),+22
Hodgkin disease, chemotherapy, radiotherapy
39M/73RAEB44-45,XY,dic(5;17)(q11;p11),+8,-13,-21,+1-2mar/45-47,idem,+13,t(15;18)(q10;q10),+i(21)(q10)
40M/79AML-M644,XY,add(2)(q21),dic(5;17)(q13;p11),-7,+8,add(12)(p11),-15,-16,+mar
41M/39AML45,XY,-3,r(5)(p14q11),-7,+der(19)t(3;19)(q2?5;q13)/44,XY,-3,dic(5;17)(q12;p11),-7,+mar/ 44,XY,t(3;15) (p2?3;q15),dic(5;12)(q12;p11),-7,add(10)(p13)
squamous cell carcinoma, chemotherapy, radiotherapy

Abbreviations: CML, chronic myeloid leukemia; RAEB, Refractory anemia with excess of blasts; AML-M2, Acute myeloblastic leukemia with maturation (FAB type M2); AML-M1, Acute myeloblastic leukemia without maturation (FAB type M1); AML, Acute myeloid leukemia, NOS; AML-M6, Acute erythroleukemia (FAB type M6); MDS, Myelodysplastic syndrome; AML-M7, Acute megakaryoblastic leukemia (FAB type M7).
1. Hagemeijer et al., 1981; 2. Knapp et al., 1985; 3. Huret et al., 1991; 4. Kerim et al., 1991; 5. Heyn et al., 1994; 6. Kwong et al., 1994; 7. Hatzis et al., 1995; 8. Arkesteijn et al., 1996;  9-10. Tosi et al., 1996; 11-24. Wang et al., 1997;  25.Mrozek et al., 2002; 26. Nakamori et al., 2003; 27.Andersen et al., 2005; 28-33.Andersen et al., 2005; 34. Zatkova et al., 2006; 35-37. Herry et al., 2007; 38. Andersen et al., 2008; 39.Lange et al., 2010; 40. Hangai et al., 2013;  41. McNerney et al., 2014.
Phenotype / cell stem origin Phenotype / cell stem origin de novo and therapy related myeloid malignancies.
Epidemiology 29 male and 12 female patients (sex ratio 2.4) aged 1 to 86 years (median age 63 years). There were 2 pediatric cases (aged 1 and 8 years), both of them developed AML after therapy for rhabdomyosarcoma.
Prognosis Patients with 5q and/or 17p deletions and complex karyotypes represent an unfavorable cytogenetic prognostic category, particularly when the disorder is related to previous cytotoxic therapy.

Cytogenetics

Cytogenetics Morphological Presents as 1 normal chromosome 5 and 17 and a dic(5;17) chromosome that contains the short arm of chromosome 5, the long arm of chromosome 17 and centromeres of both chromosomes; breakpoints at or near the centromeres may be difficult to ascertain, the most common described breakpoints were q11 on chromosome 5 and p11 on 17p, reported in 31 out of 41 patients. Combining karyotyping with fluorescence in situ hybridization of centromere-specific probes for chromosomes 5 and 17 allows precise breakpoint definition and confirm the presence of both centromeres.
Additional anomalies Sole anomaly in 1 MDS patient previously treated for acute promyelocytic leukemia and found in association with increased karyotype complexity in most of the cases. The most commonly observed anomaly was monosomy 7, observed in 19, while 7q deletion was found in 5 patients. Monosomy 5/5q- was found in 4 and +8 in 10 patients.

Result of the chromosomal anomaly

Fusion Protein
Oncogenesis Deletion of 5q and 17p through formation of an unbalanced dicentric rearrangement is a non-random event in myeloid malignancies, particularly in therapy-related disorders. dic(5;17)(q11-14;p11-13) result in partial monosomy for 5q and 17p leading to altered gene dosages, affecting tumor suppressor genes. The key mechanism might be the combined loss of tumor suppressor genes in 5q and 17p containing the TP53 gene. It is likely that TP53 loss that is frequently accompanied by inactivating mutations in the remaining TP53 allele (Wang et al., 1997) represent one of the instigators of the genome instability that is manifested by complex karyotypes. Highly complex rearrangements containing unbalanced translocations, ring chromosomes, insertions, marker chromosomes, homogeneously staining regions, dicentric chromosomes and cytogenetically unrelated clones were overrepresented in patients with therapy-related myeloid malignancies, indicative of the role of mutagenic effect of previous therapy. The probable sequence of genetic events is unclear; however dic(5;17) usually presents with additional common anomalies such as monosomy 7/7q or 5/5q and trisomy 8, therefore the formation of dic(5;17) likely represent a therapy-induced abnormality that occurred during the multistep process of leukemogenesis
  

Bibliography

Centromeric breakage and highly rearranged chromosome derivatives associated with mutations of TP53 are common in therapy-related MDS and AML after therapy with alkylating agents: an M-FISH study
Andersen MK, Christiansen DH, Pedersen-Bjergaard J
Genes Chromosomes Cancer 2005 Apr;42(4):358-71
PMID 15645489
 
NPM1 mutations in therapy-related acute myeloid leukemia with uncharacteristic features
Andersen MT, Andersen MK, Christiansen DH, Pedersen-Bjergaard J
Leukemia 2008 May;22(5):951-5
 
The use of FISH with chromosome-specific repetitive DNA probes for the follow-up of leukemia patients
Arkesteijn GJ, Erpelinck SL, Martens AC, Hagemeijer A, Hagenbeek A
Correlations and discrepancies with bone marrow cytology Cancer Genet Cytogenet
PMID 8630983
 
Translocation (5p; 17q) in blast crisis of chronic myeloid leukemia
Hagemeijer A, Sizoo W, Smit EM, Abels J
Cytogenet Cell Genet 1981;30(4):205-10
PMID 6945934
 
Erythroleukemia showing early erythroid and cytogenetic responses to azacitidine therapy
Hangai S, Nakamura F, Kamikubo Y, Honda A, Arai S, Nakagawa M, Ichikawa M, Kurokawa M
Ann Hematol 2013 May;92(5):707-9
PMID 23070126
 
Acute promyelocytic leukaemia (M3): relapse with acute myeloblastic leukaemia (M2) and dic(5;17) (q11;p11)
Hatzis T, Standen GR, Howell RT, Savill C, Wagstaff M, Scott GL
Am J Hematol 1995 Jan;48(1):40-4
PMID 7832190
 
Evaluation of chromosome 5 aberrations in complex karyotypes of patients with myeloid disorders reveals their contribution to dicentric and tricentric chromosomes, resulting in the loss of critical 5q regions
Herry A, Douet-Guilbert N, Morel F, Le Bris MJ, Morice P, Abgrall JF, Berthou C, De Braekeleer M
Cancer Genet Cytogenet 2007 Jun;175(2):125-31
PMID 17556068
 
Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: an interim report
Heyn R, Khan F, Ensign LG, Donaldson SS, Ruymann F, Smith MA, Vietti T, Maurer HM
Med Pediatr Oncol 1994;23(2):99-106
PMID 8202048
 
Two additional cases of isochromosome 21q or translocation 21q21q in hematological malignancies
Huret JL, Schoenwald M, Gabarre J, Vaugier GL, Tanzer J
Acta Haematol 1991;86(2):111-4
PMID 1950371
 
Trisomy 8 and an unbalanced t(5;17)(q11;p11) characterize two karyotypically independent clones in a case of idiopathic myelofibrosis evolving to acute nonlymphoid leukemia
Kerim S, Rege-Cambrin G, Scaravaglio P, Godio L, Saglio G, Aglietta M
Cancer Genet Cytogenet 1991 Mar;52(1):63-9
PMID 2009512
 
Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes
Knapp RH, Dewald GW, Pierre RV
Mayo Clin Proc 1985 Aug;60(8):507-16
PMID 3860707
 
Cytogenetic triclonality in acute myeloid leukemia: a morphologic, immunologic and in situ hybridization study
Kwong YL, Lam CK, Chan AY, Lie AK, Chan LC
Cancer Genet Cytogenet 1994 Feb;72(2):86-91
PMID 8143281
 
Telomere shortening and chromosomal instability in myelodysplastic syndromes
Lange K, Holm L, Vang Nielsen K, Hahn A, Hofmann W, Kreipe H, Schlegelberger B, Göhring G
Genes Chromosomes Cancer 2010 Mar;49(3):260-9
PMID 19998444
 
The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7/del(7q)
McNerney ME, Brown CD, Peterson AL, Banerjee M, Larson RA, Anastasi J, Le Beau MM, White KP
Br J Haematol 2014 Aug;166(4):550-6
PMID 24931631
 
Spectral karyotyping in patients with acute myeloid leukemia and a complex karyotype shows hidden aberrations, including recurrent overrepresentation of 21q, 11q, and 22q
Mrózek K, Heinonen K, Theil KS, Bloomfield CD
Genes Chromosomes Cancer 2002 Jun;34(2):137-53
PMID 11979548
 
Therapy-related erythroleukemia caused by the administration of UFT and mitomycin C in a patient with colon cancer
Nakamori Y, Miyazaki M, Tominaga T, Taguchi A, Shinohara K
Int J Clin Oncol 2003 Feb;8(1):56-9
PMID 12601545
 
Classification of deletions and identification of cryptic translocations involving 7q by fluorescence in situ hybridization (FISH)
Tosi S, Harbott J, Haas OA, Douglas A, Hughes DM, Ross FM, Biondi A, Scherer SW, Kearney L
Leukemia 1996 Apr;10(4):644-9
PMID 8618441
 
dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53
Wang P, Spielberger RT, Thangavelu M, Zhao N, Davis EM, Iannantuoni K, Larson RA, Le Beau MM
Genes Chromosomes Cancer 1997 Nov;20(3):282-91
PMID 9365836
 
GAB2 is a novel target of 11q amplification in AML/MDS
Zatkova A, Schoch C, Speleman F, Poppe B, Mannhalter C, Fonatsch C, Wimmer K
Genes Chromosomes Cancer 2006 Sep;45(9):798-807
PMID 16736498
 

Citation

This paper should be referenced as such :
Zamecnikova A, al Bahar S
dic(5;17)(q11-14;p11-13);
Atlas Genet Cytogenet Oncol Haematol. in press
On line version : http://AtlasGeneticsOncology.org/Anomalies/dic0517q11p11ID1164.html


External links

arrayMapMorph ( 9975/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
arrayMapMorph ( 9989/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
arrayMapMorph ( 9920/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
arrayMapMorph ( 9861/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
 
 
Disease databasedic(5;17)(q11-14;p11-13)
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Mar 14 13:53:47 CET 2017


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.